Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

SELL
$1.92 - $2.71 $1,436 - $2,027
-748 Reduced 0.99%
74,641 $197,000
Q3 2023

Nov 13, 2023

BUY
$1.9 - $3.16 $258 - $429
136 Added 0.18%
75,389 $152,000
Q1 2023

May 11, 2023

BUY
$2.26 - $4.22 $170,071 - $317,567
75,253 New
75,253 $188,000

Others Institutions Holding ATHA

About Athira Pharma, Inc.


  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $24.2M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Cornercap Investment Counsel Inc Portfolio

Follow Cornercap Investment Counsel Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cornercap Investment Counsel Inc with notifications on news.